NCT04956809

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 3 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

Conditions

• HFrEF

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10Mg Tab	This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.
DRUG	Placebo	This will be a single-center randomized, placebo controlled, double-blind, 2-treatment, 2-phase cross-over trial in 27 HFrEF subjects: (A) Dapa 10 mg daily; (B) Placebo.

Timeline

• Start date: 2021-10-22
• Primary completion: 2023-06-01
• Completion: 2023-06-01
• First posted: 2021-07-09
• Last updated: 2023-12-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study